The Food and Drug Administration (FDA) has approved Hyftor™ (sirolimus topical gel) for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in patients 6 years ...

Hyftor (sirolimus topical gel) 0.2%, which previously received orphan drug status, is the first topical treatment indicated for the treatment of facial angiofibroma in tuberous sclerosis complex.

Tuberous sclerosis complex (TSC) is a rare genetic condition that causes non-cancerous (benign) tumors in various organs of the body, including in the brain. It is also accompanied by patches of ...

Tuberous sclerosis complex (TSC) is a genetic condition which affects how your cells divide. Growths can occur in many places in your body including, your skin, lungs, kidneys, heart and brain.

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects multiple organ systems and is caused by loss-of-function mutations in one of two genes: TSC1 or TSC2. The disorder ...